Effect of mosapride citrate on gastric emptying in interferon-induced gastroparesis

Digestive Diseases and Sciences

Volumn 57, Issue 6, 2012, Pages 1510-1516

  Kawamura, Etsushi ^a   Enomoto, Masaru ^a   Kotani, Kohei ^a   Hagihara, Atsushi ^a   Fujii, Hideki ^a   Kobayashi, Sawako ^a   Iwai, Shuji ^a   Morikawa, Hiroyasu ^a   Kawabe, Joji ^a   Tominaga, Kazunari ^a   Tamori, Akihiro ^a   Shiomi, Susumu ^a   Kawada, Norifumi ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

5 HT 4 receptor agonist; Chronic hepatitis C; Gastric emptying scintigraphy; Gastroparesis; Pegylated interferon

Indexed keywords

MOSAPRIDE; PEGINTERFERON; PEGINTERFERON ALPHA2B; PENTETATE TECHNETIUM TC 99M; RIBAVIRIN;

ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEPATITIS C; HUMAN; LEUKOPENIA; MALE; OPEN STUDY; PRIORITY JOURNAL; PROTEINURIA; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STOMACH EMPTYING; STOMACH MOTILITY; STOMACH PARESIS; STOMACH SCINTISCANNING; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; BENZAMIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GASTRIC EMPTYING; GASTROPARESIS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MORPHOLINES; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; REFERENCE VALUES; RIBAVIRIN; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 84864282352     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2085-8     Document Type: Article

References (32)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558-567. (Pubitemid 41196755)
2. Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153-156. (Pubitemid 32911406)
3. Barazani Y, Hiatt JR, Tong MJ, et al. Chronic viral hepatitis and hepatocellular carcinoma. World J Surg. 2007;31:1243-1248. (Pubitemid 47029929)
4. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360:1827-1838.
5. Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360:1839-1850.
6. Kwo PY, Lawitz EJ, McCone J, et al. SPRINT-1 investigators. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376: 705-716.
7. Oze T, Hiramatsu N, Yakushijin T, et al. Pegylated interferon alpha-2b (PegIFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with PegIFN alpha-2b plus ribavirin. J Viral Hepat. 2009;16:578-585.
8. Bagheri H, Fouladi A, Barange K, et al. Follow-up of adverse drug reactions from peginterferon alfa-2b-ribavirin therapy. Pharmacotherapy. 2004;24:1546-1553. (Pubitemid 39426351)
9. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology. 2006;130:1466-1479.
10. Nishiguchi S, Shiomi S, Kurooka H, et al. Randomized trial assessing gastric emptying in patients with chronic hepatitis C during interferon-alpha or -beta therapy and effect of cisapride. Dig Dis Sci. 2002;47:73-78. (Pubitemid 34075020)
11. Chen C, Chao Y, Chang F, et al. Intracisternal des-acyl ghrelin inhibits food intake and non-nutrient gastric emptying in conscious rats. Int J Mol Med. 2005;16:695-699.
12. Curran M, Robinson D. Mosapride in gastrointestinal disorders. Drugs. 2008;68:981-991.
13. Gatto G, Ricca T, Randazzo MA, et al. Clinical efficacy and safety of levosulpridine and domperidone in the management of chronic functional dyspepsia: a double-blind, randomized clinical trial. Curr Ther Res Clin Exp. 1992;51:715-722.
14. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958-965. (Pubitemid 32913521)
15. Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol. 1996;25:591-598. (Pubitemid 26373872)
16. Raber J, Koob G, Bloom F. Interferon-alpha and transforming growth factor-beta 1 regulate corticotropin-releasing factor release from the amygdala: comparison with the hypothalamic response. Neurochem Int. 1997;30:455-463. (Pubitemid 27136027)
17. Neal CR Jr, Mansour A, Reinscheid R, et al. Opioid receptor-like (ORL1) receptor distribution in the rat central nervous system: comparison of ORL1 receptor mRNA expression with (125) I-[(14)Tyr]-orphanin FQ binding. J Comp Neurol. 1999;412: 563-605. (Pubitemid 29409672)
18. Olszewski PK, Grace MK, Sanders JB, et al. Effect of nociceptin/orphanin FQ on food intake in rats that differ in diet preference. Pharmacol Biochem Behav. 2002;73:529-535. (Pubitemid 34879161)
19. Martínez V, Wang L, Rivier J, et al. Differential actions of peripheral corticotropin-releasing factor (CRF), urocortin II, and urocortin III on gastric emptying and colonic transit in mice: role of CRF receptor subtypes 1 and 2. J Pharmacol Exp Ther. 2002; 301:611-617. (Pubitemid 34429975)
20. Broccardo M, Scaccianoce S, Del Bianco P, et al. Nociceptin/orphanin FQ-induced delay in gastric emptying: role of central corticotropin-releasing factor and glucocorticoid receptors. Neurogastroenterol Motil. 2005;17:871-877. (Pubitemid 41746525)
21. Lenz H, Raedler A, Greten H, et al. Stress-induced gastrointestinal secretory and motor responses in rats are mediated by endogenous corticotropin-releasing factor. Gastroenterology. 1988; 95:1510-1517. (Pubitemid 19016208)
22. Kahraman H, Kaya N, Demirçali A, et al. Gastric emptying time in patients with primary hypothyroidism. Eur J Gastroenterol Hepatol. 1997;9:901-904. (Pubitemid 27404419)
23. Samsom M, Bharucha A, Gerich JE, et al. Diabetes mellitus and gastric emptying: questions and issues in clinical practice. Diabetes Metab Res Rev. 2009;25:502-514.
24. Taniyama K, Makimoto N, Furuichi A, et al. Functions of peripheral 5-hydroxytryptamine receptors, especially 5-hydroxy-tryptamine4 receptor, in gastrointestinal motility. J Gastroenterol. 2000;35:575-582. (Pubitemid 30649493)
25. Ishizu H, Shiomi S, Kawamura E, et al. Gastric emptying in patients with chronic liver diseases. Ann Nucl Med. 2002;16: 177-182. (Pubitemid 34717568)
26. Sarnelli G, Caenepeel P, Geypens B, et al. Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol. 2003;98:783-788. (Pubitemid 36576302)
27. Tomita R. Gastric emptying function in patients 5 years after pylorus-preserving distal gastrectomy with or without preserving pyloric and hepatic branches of the vagal nerve for early gastric cancer. World J Surg. 2009;33:2119-2126.
28. Braden B, Adams S, Duan LP, et al. The [13C] acetate breath test accurately reflects gastric emptying of liquids in both liquid and semisolid test meals. Gastroenterology. 1995;108:1048-1055.
29. Wang J, Song J, Hou X, et al. Effects of cutaneous gastric electrical stimulation on gastric emptying and postprandial satiety and fullness in lean and obese subjects. J Clin Gastroenterol. 2010;44:335-339.
30. De la Roca-Chiapas JM, Córdova-Fraga T, Reynaga G, et al. Scintigraphy versus mechanical magnetogastrography: gastric emptying analysis. Med Biol Eng Comput. 2010;48:727-729.
31. Camilleri M, Hasler W, Parkman H, et al. Measurement of gastrointestinal motility in the GI laboratory. Gastroenterology. 1998;115:747-762. (Pubitemid 28397311)
32. Tougas G, Eaker EY, Abell TL, et al. Assessment of gastric emptying using a low fat meal: establishment of international control values. Am J Gastroenterol. 2000;95:1456-1462. (Pubitemid 30396302)